External beam radiotherapy for stage T1/T2 prostate cancer: How does it stack up?

Urology

Volumn 51, Issue 2, 1998, Pages 258-264

  Pollack, Alan ^a   Zagars, Gunar K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RADIATION DOSE; TRANSURETHRAL RESECTION; TREATMENT OUTCOME;

ACTUARIAL ANALYSIS; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; SURVIVAL RATE;

EID: 0032006282     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00621-3     Document Type: Article

References (24)

1. Zagars GK, Pollack A. Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome. Urology. 45:1995;476-483.
2. Hanks GE, Schultheiss TE, Hanlon HA, Hunt M, Lee WR, Epstein BE, Coia LR. Optimization of conformal radiation treatment of prostate cancer: report of a dose escalation study. Int J Radiat Oncol Biol Phys. 37:1997;543-550.
3. Stein A, deKernion JB, Smith RB, Dorey F, Patel H. Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J Urol. 147:1992;942-946. (3 Pt 2).
4. Partin A, Pound CR, Quentin Clements J, Epstein JI, Walsh PC. Serum PSA after anatomic radical prostatectomy: the Johns Hopkins experience after 10 years. Urol Clin North Am. 20:1993;713-725.
5. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, Wein A. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol. 154:1995;131-138.
6. Kupelian P, Katcher J, Levin H, Zippe C, Klein E. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology. 48:1996;249-260.
7. Zietman A, Edelstein RA, Coen JJ, Babayan RK, Krane RJ. Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology. 43:1994;828-833.
8. Pollack A, Zagars GK. External beam radiotherapy dose-response of prostate cancer. Int J Radiat Oncol Biol Phys. 39:1997;1011-1018.
9. Roy AV, Bower ME, Hayden JE. Sodium thymolphthalein monophosphate: a new acid phosphatase substrate with greater specificity for the prostatic enzyme inserum. Clin Chem. 17:1971;1093-1102.
10. Pollack A, Zagars GK, Starkschall G, Childress CH, Kopplin S, Boyer AL, Rosen II. Conventional versus conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys. 34:1996;555-564.
11. Altman DG. Practical Statistics for Medical Research. 1991;179-268 Chapman and Hall, London, UK.
12. Harris EK, Albert A. Survivorship Analysis for Clinical Studies. 1991;5-125 Marcel Dekker, New York.
13. Cox DR, Oakes D. Analysis of Survival Data. 1984;110-120 Chapman and Hall, London.
14. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol. 152:1994;1837-1842. (5 Pt 2).
15. 125iodine implantation for stage T1/T2 prostatic carcinoma. J Urol. 154:1995;1096-1099.
16. Stock RG, Stone NN, DeWyngaert JK, Lavagnini P, Unger PD. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Cancer. 77:1996;2386-2392.
17. Wallner K, Roy J, Harrison L. Tumor control and morbidity following transperineal iodine-125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol. 14:1996;449-453.
18. 125I prostate implantation. Int J Radiat Oncol Biol Phys. 37:1997;559-563.
19. Roach M III, Burton E, Kroll S, Bevins S, Ryu JK, Holland JM, Hunter DC, Rosenthal S, Margolis LW, Phillips TL. 501 men irradiated for clinically localized prostate cancer (1987-1995): preliminary analysis of the experience at UCSF and affiliated facilities. Int J Radiat Oncol Biol Phys. 36:1996;248. (suppl).
20. Zelefsky MJ, Leibel SA, Kelson S, Fuks Z. Impact of radiation dose on achieving nadir PSA levels after 3-dimensional conformal radiotherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 36:1996;196. (suppl).
21. Roy JN, Wallner KE, Harrington PJ, Ling CC, Anderson LL. A CT-based evaluation method for permanent implants: application to the prostate. Int J Radiat Oncol Biol Phys. 26:1993;163-169.
22. Partin AW, Kattan MW, Subong ENP, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. JAMA. 277:1997;1445-1451.
23. Zagars GK, Pollack A, von Eschenbach AC. Prognostic factors in clinically localized prostate carcinoma - analysis of 938 patients irradiated in the prostate specific antigen era. Cancer. 79:1997;1370-1380.
24. Pisansky TM, Kahn MJ, Rasp GM, Cha SS, Haddock MG, Bostwick DG. A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma. Cancer. 79:1997;337-344.